Navigation Links
UCI non-small cell lung cancer study highlights advances in targeted drug therapy
Date:11/1/2010

Orange, Calif., Nov 1, 2010 A UC Irvine oncologist's work with a targeted therapy is showing great promise in patients with a deadly form of lung cancer. The results were published Thursday in the New England Journal of Medicine.

The multicenter study is testing whether the drug crizotinib effectively slows, stops or reverses growth in advanced non-small cell lung cancer tumors by targeting a genetic mutation that causes uncontrolled tumor growth. Study participants all tested positive for a mutation in the anaplastic lymphoma kinase gene.

According to the findings, tumors disappeared or shrank in 57 percent of patients. Tumors ceased growing in another 33 percent. The response rate to the current standard of care for advanced non-small cell lung cancer is about 15 percent.

"For the majority of patients, the treatment right now is chemotherapy plus targeted therapy in those eligible," said Dr. Ignatius Ou. "In the future, with the advance of personalized medicine, we hope to be able to identify specific genetic change in the lung cancer and treat patients with specific inhibitors that can improve survival rates and quality of life."

The New England Journal of Medicine article includes data from 82 patients treated in Phase 1 of this study, sponsored by the pharmaceutical company Pfizer. The targeted genetic mutation is particularly prevalent among those who have never smoked. Study participants ranged in age from 25 to 78, with 76 percent of them nonsmokers.

Ou treated 15 patients in UCI's Phase 1 trial, most from Los Angeles, Orange and San Diego counties. One person came from Arizona each month for treatment and assessment. Ou is currently enrolling patients in Phase 2 and 3 trials for crizotinib. Interested candidates should contact the UCI clinical trials office at 714-456-6241.

Each year, about 1.5 million new cases of lung cancer are diagnosed globally. Nearly 75 percent of people with non-small cell lung cancer are diagnosed at an advanced stage, for which the five-year survival rate is only 6 percent.

Recent cancer research emphasizes targeting, or personalizing, treatment through molecular analysis of a tumor and the use of a specific drug to inhibit genetic expression. Conventional chemotherapy bombards a tumor with multiple drugs.

According to the National Cancer Institute, because targeted cancer therapies are more selective for cancer cells, they may harm fewer normal cells, reduce side effects and improve quality of life.


'/>"/>

Contact: John Murray
jdmurray@uci.edu
714-456-7759
University of California - Irvine
Source:Eurekalert

Related medicine news :

1. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
2. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
3. Research identifies patterns of CD24, a novel biomarker for non-small cell lung carcinomas
4. Genentech uses Complete Genomics human genome sequencing service to compare tumor and normal genome in patient with non-small cell lung cancer; results published in Nature
5. Comparision of overall survival for non-small cell lung cancer patients
6. Enhancing arrest of cell growth to treat cancer in mice
7. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
8. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
9. Low forms of cyclin E reduce breast cancer drugs effectiveness
10. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
11. Soft drinks may increase risk of pancreatic cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2016)... ... November 30, 2016 , ... "I hate when the mixture ... brushing my teeth," said an inventor from Bridgewater, N.J. "I thought that there had ... handy device." , He developed the patent-pending DEFLECTOR to prevent saliva and toothpaste from ...
(Date:11/30/2016)... FL (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new eating ... partial hospitalization and intensive outpatient treatment for adults and adolescents, both males and ...
(Date:11/30/2016)... , ... November 30, 2016 , ... ... injured workers have been a focus of public policymakers and system stakeholders in ... Institute (WCRI) released its Medical Price Index for Workers’ Compensation, Eighth Edition ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... clinical research community that the FDA Binding Guidance goes into effect next month. ... formats listed in the FDA Data Standards Catalog. The current FDA Data Standards ...
(Date:11/30/2016)... ... 2016 , ... U.S. Security Associates (USA) announced the acquisition ... Richmond, Virginia. The acquisition further strengthens USA’s capabilities within the expanding healthcare ... prides itself on 100% client-retention to the healthcare industry. In addition, ODS has ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... YORK , December 2, 2016 ... the trading session in red, while the Dow Jones Industrial ... at the close of US markets, which prompted Stock-callers this ... stocks: NuVasive Inc. (NASDAQ: NUVA ), Smith & ... (NASDAQ: NXTM ), and Cesca Therapeutics Inc. (NASDAQ: ...
(Date:12/2/2016)... LONDON , Dec. 1, 2016 Around ... every country, region and each habitable land present over ... haunt every individual once in a life time this ... proper care available until now. Given the steady increase ... mortality, together with the spiraling healthcare costs of treatment, ...
(Date:11/30/2016)... Research and Markets has announced the addition ... - MedCore" report to their offering. ... , , The cerebrospinal fluid ... healthy individuals, it is circulated though the brain and its ventricles, the ... of CSF surrounding the brain changes significantly. As ...
Breaking Medicine Technology: